OverviewSuggest Edit

Zoetis is a company engaged in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products. It offers vaccines, anti-infectives, parasiticides, other pharmaceutical products, dermatology, medicated feed additives, and animal health diagnostics for cattle, swine, poultry, fish, and sheep as well as dogs, cats, and horses.
TypePublic
Founded2012
HQParsippany-Troy Hills, NJ, US
Websitezoetis.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Dec 2019)10,600(+6%)
Revenue (FY, 2019)$6.3 B(+8%)
Share Price (Jan 2021)$161.6
Cybersecurity ratingBMore

Key People/Management at Zoetis

Kristin Peck

Kristin Peck

Chief Executive Officer and Director
Tim Bettington

Tim Bettington

Executive Vice President and President, U.S. Operations
Glenn David

Glenn David

Executive Vice President and Chief Financial Officer
Heidi Chen

Heidi Chen

Executive Vice President, General Counsel and Corporate Secretary
Rob Kelly

Rob Kelly

Executive Vice President and President, International Operations
Cathy Knupp

Cathy Knupp

Executive Vice President and President, Research and Development
Show more

Zoetis Office Locations

Zoetis has offices in Parsippany-Troy Hills, DXS, Silverwater, Wien and in 46 other locations
Parsippany-Troy Hills, NJ, US (HQ)
10 Sylvan Way, Parsippany
DXS, AR
Virrey Loreto 2477
Wien, AT
Floridsdorfer Hauptstraße 1
Zaventem, BE
Mercuriusstraat 20
Sao Paulo, BR
Rua Luiz Fernando Rodrigues 1701
Kirkland, CA
16740 Route Transcanadienne
Show all (51)

Zoetis Financials and Metrics

Zoetis Revenue

Embed Graph
View revenue for all periods
Zoetis's revenue was reported to be $6.26 b in FY, 2019 which is a 7.5% increase from the previous period.
USD

Revenue (Q3, 2020)

1.8b

Gross profit (Q3, 2020)

1.2b

Gross profit margin (Q3, 2020), %

69.4%

Net income (Q3, 2020)

479.0m

Market capitalization (15-Jan-2021)

76.8b

Closing stock price (15-Jan-2021)

161.6

Cash (30-Sept-2020)

3.7b

EV

81.0b
Zoetis's current market capitalization is $76.8 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

5.3b5.8b6.3b

Revenue growth, %

10%7%

Cost of goods sold

1.8b1.9b2.0b

Gross profit

3.5b3.9b4.3b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

1.4b1.4b1.5b1.5b1.5b1.6b1.5b1.5b1.8b

Cost of goods sold

447.0m447.0m473.0m518.0m465.0m479.0m459.0m451.0m546.0m

Gross profit

919.0m968.0m1.0b937.0m1.1b1.1b1.1b1.1b1.2b

Gross profit Margin, %

67%68%68%64%70%70%70%71%69%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

1.6b1.6b1.9b

Accounts Receivable

998.0m1.0b1.1b

Inventories

1.4b1.4b1.4b

Current Assets

4.2b4.4b4.7b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

1.7b1.6b1.3b1.7b1.8b1.8b2.0b3.4b3.7b

Accounts Receivable

943.0m973.0m929.0m970.0m994.0m1.0b965.0m984.0m1.0b

Inventories

1.4b1.4b1.4b1.4b1.4b1.4b1.5b1.6b1.6b

Current Assets

4.3b4.2b4.1b4.4b4.5b4.6b4.8b6.3b6.8b
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

862.0m1.4b1.5b

Depreciation and Amortization

242.0m308.0m412.0m

Inventories

19.0m61.0m(104.0m)

Accounts Payable

(10.0m)37.0m(10.0m)
Quarterly
USDFY, 2017

EV/CFO

28.6 x

Revenue/Employee

576.8k

Debt/Equity

2.8 x

Debt/Assets

0.6 x

Financial Leverage

4.8 x

P/E Ratio

41.0
Show all financial metrics

Zoetis Operating Metrics

FY, 2017Q1, 2018Q2, 2018Q3, 2018FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019Q1, 2020Q2, 2020Q3, 2020

Product Lines

300 300 300 300 300 300 300 300 300 300 300 300

Countries

100 100 100 100 100 100 100 100 100 100 100 100

Patents Issued

5.20 k5.50 k6 k

Trademarks

10 k10 k7.90 k
Show all operating metrics

Zoetis Acquisitions / Subsidiaries

Company NameDateDeal Size
Performance Livestock AnalyticsApril 08, 2020
Ethos Diagnostic ScienceFebruary 07, 2020
Platinum PerformanceJuly 22, 2019
AbaxisMay 15, 2018$1.90 b
NexvetApril 03, 2017$85 m
Scandinavian Micro BiodevicesAugust 08, 2016$80 m
PHARMAQNovember 02, 2015$765 m
BovigenMarch 18, 2008
Abaxis Asia Holding Limited
Abaxis Europe GmbH
Show more

Zoetis Revenue Breakdown

Embed Graph

Zoetis revenue breakdown by business segment: 7.6% from Medicated Feed Additives, 12.4% from Dermatology, 12.6% from Other Pharmaceuticals, 15.6% from Parasiticides, 20.2% from Anti-infectives, 23.9% from Vaccines and 7.6% from Other

Zoetis revenue breakdown by geographic segment: 6.0% from Other Developed Markets, 12.0% from Other Emerging Markets, 51.9% from United States and 30.2% from Other

Zoetis Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Zoetis Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Zoetis Online and Social Media Presence

Embed Graph

Zoetis News and Updates

Europe Companion Animal Diagnostics Market Set to Expand by 2020-2027 Focusing on Key Players Zoetis Inc, Randox Laboratories, Ltd., Idexx Laboratories, Inc., IDvet, Virbac

The Europe companion animal diagnostics market is to reach US$ 792.8 million by 2027 from US$ 613.6 million in 2019. The market is anticipated to grow at a CAGR of 3.8% during 2019–2027. Posted via Industry Today. Follow us on Twitter @IndustryToday

Companion Animal Diagnostics Market examined in new market research report by top companies Skyla, Randox Laboratories, IDEXX Laboratories, Zoetis

The companion animal diagnostics marketwas valued at US$ 2,031.62 million in2019 and is projected to reach US$ 2,684.86 million by 2027; it is expected to grow at a CAGR of 4.1%from 2020to 2027. Posted via Industry Today. Follow us on Twitter @IndustryToday

Animal Prescription Drugs Market SWOT Analysis by Key Players- Elanco Animal Health, Zoetis, Virbac, Dechra

Stay up-to-date with Animal Prescription Drugs Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. Posted via Industry Today. Follow us on Twitter @IndustryToday

Consider Adding Zoetis, Garmin, And Intuit To Your Retirement Portfolio

Are you retiring? Or do you want to build a portfolio that offers steady returns with minimal risk? Then consider Zoetis, Garmin, Intuit, Roper Technologies, and Amphenol. When it comes to retirement, stability is the key. Thus, we identified these 5 companies that are worthy candidates for your...

$13.7 Billion Worldwide Animal Parasiticides Industry to 2025 - Featuring Merck, Zoetis & Virbac Among Others

DUBLIN, July 15, 2020 /PRNewswire/ -- The "Animal Parasiticides Market by Product (Ectoparasiticides, Endectocide (Ear Tags, Tablets, Dips, Injectables, Spot-on, Collars) Animal (Dogs, Cats, Cattle, Sheep, Goats, Horses) End-user (Veterinary Hospitals) - Global Forecast to 2025" report...

Zoetis Announces Pricing of $1.25 Billion of Senior Notes

Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.25 billion of senior notes, consisting of $750 million aggregate principal amount of 2.000% senior notes due 2030 and $500 million aggregate principal amount of 3.000% senior notes due 2050, in an underwritten public offering.
Show more

Zoetis Frequently Asked Questions

  • When was Zoetis founded?

    Zoetis was founded in 2012.

  • Who are Zoetis key executives?

    Zoetis's key executives are Kristin Peck, Tim Bettington and Glenn David.

  • How many employees does Zoetis have?

    Zoetis has 10,600 employees.

  • What is Zoetis revenue?

    Latest Zoetis annual revenue is $6.3 b.

  • What is Zoetis revenue per employee?

    Latest Zoetis revenue per employee is $590.6 k.

  • Who are Zoetis competitors?

    Competitors of Zoetis include Elanco, IDEXX Laboratories and Bayer.

  • Where is Zoetis headquarters?

    Zoetis headquarters is located at 10 Sylvan Way, Parsippany, Parsippany-Troy Hills.

  • Where are Zoetis offices?

    Zoetis has offices in Parsippany-Troy Hills, DXS, Silverwater, Wien and in 46 other locations.

  • How many offices does Zoetis have?

    Zoetis has 51 offices.